{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05013216",
            "orgStudyIdInfo": {
                "id": "J2177"
            },
            "secondaryIdInfos": [
                {
                    "id": "IRB00288752",
                    "type": "OTHER",
                    "domain": "Johns Hopkins Medical Institution"
                }
            ],
            "organization": {
                "fullName": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
                "class": "OTHER"
            },
            "briefTitle": "Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer",
            "officialTitle": "Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "mutant-kras-targeted-long-peptide-vaccine-for-patients-at-high-risk-of-developing-pancreatic-cancer"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-09",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-04-11",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-05-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-05-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-08-18",
            "studyFirstSubmitQcDate": "2021-08-18",
            "studyFirstPostDateStruct": {
                "date": "2021-08-19",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-09-01",
            "lastUpdatePostDateStruct": {
                "date": "2023-09-05",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "Stand Up To Cancer",
                    "class": "OTHER"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This Phase 1 study will evaluate safety and the immune response to pooled mutant-KRAS peptide vaccine with poly-ICLC adjuvant."
        },
        "conditionsModule": {
            "conditions": [
                "High Risk Cancer",
                "Pancreatic Cancer"
            ],
            "keywords": [
                "KRAS Peptide Vaccine",
                "Neoantigen Vaccines",
                "Cancer Vaccines",
                "Immunotherapy",
                "Pancreatic Ductal Adenocarcinoma (PDAC)"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "PREVENTION",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 25,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "KRAS peptide vaccine",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: KRAS peptide vaccine"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "KRAS peptide vaccine",
                    "description": "1. KRAS peptide vaccine will be administered on Prime week 1, 3, and 5. Boost vaccinations with will be administered at week 13.\n2. Drug: up to 1.8 mg KRAS peptide vaccine + 0.5mg Poly-ICLC",
                    "armGroupLabels": [
                        "KRAS peptide vaccine"
                    ],
                    "otherNames": [
                        "Hiltonol\u00ae (Poly-ICLC)"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number of participants experiencing study drug-related toxicities",
                    "description": "Number of participants experiencing study drug-related adverse events Grade 3 or higher as defined by CTCAE v5.0",
                    "timeFrame": "1.5 years"
                },
                {
                    "measure": "Maximal percentage of change of interferon (IFN-\u03b3) producing mutant-KRAS-specific CD8 and CD4 T cells",
                    "description": "Maximal percent change per patient within 17 weeks after vaccination.",
                    "timeFrame": "17 weeks"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Fold change in interferon-producing mutant-KRAS-specific CD8 and CD4 T cells at 5 weeks.",
                    "description": "Evaluated by the fold change in interferon-producing mutant-KRAS-specific CD8 and CD4 T cells at 5 weeks after vaccination compared to pre-vaccination baseline.",
                    "timeFrame": "Baseline, 5 weeks"
                },
                {
                    "measure": "Fold change in interferon-producing mutant-KRAS-specific CD8 and CD4 T cells at 13 weeks.",
                    "description": "Evaluated by the fold change in interferon-producing mutant-KRAS-specific CD8 and CD4 T cells at 13 weeks after vaccination compared to pre-vaccination baseline.",
                    "timeFrame": "Baseline 13 weeks"
                },
                {
                    "measure": "Fold change in interferon-producing mutant-KRAS-specific CD8 and CD4 T cells at 17 weeks.",
                    "description": "Evaluated by the fold change in interferon-producing mutant-KRAS-specific CD8 and CD4 T cells at 17 (EOT) weeks after vaccination compared to pre-vaccination baseline.",
                    "timeFrame": "Baseline,17 weeks"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\nMust fall into one of the three categories defined as high risk of developing pancreatic cancer and are undergoing pancreatic surveillance AND 2) have documented radiographic evidence of a pancreatic abnormality such as a pancreatic cyst.\n\n* High Risk Group 1 (familial pancreatic cancer relatives):\n\n  * \\>/=55 years old or 10 years younger than the age of youngest relative with pancreatic cancer, and\n  * Come from a family with 2 or more members with a history of pancreatic cancer (2 of which have a first-degree relationship consistent with familial pancreatic cancer), and\n  * Have a first-degree relationship with at least one of the relatives with pancreatic cancer.\n  * If there are 2 or more affected blood relatives, at least 1 must be a first-degree relative of the individual being screened\n* High Risk Group 2 (Germline mutation carriers with an associated with an estimated lifetime risk of pancreatic cancer of \\~10% or higher):\n\n  * \\>/=40 years old and the Patient is a carrier of FAMMM (p16/CDKN2A) mutation regardless of family pancreas cancer history.\n\nOR\n\n* \\>/= 50 years old or 10 years younger than the age of the youngest relative with pancreatic cancer, and the Patient is a carrier of a known BRCA2, ATM, PALB2 mutation.\n* Persons with known genetic mutation should have proof of mutation status. Those who had research-related genetic testing must have confirmation by a clinical CLIA-certified laboratory.\n\n  o High Risk Group 3 (Germline mutation carriers with an associated with an estimated lifetime risk of pancreatic cancer of \\~5%):\n* \\>/= 50 years old or 10 years younger than the age of the youngest relative with pancreatic cancer, and\n* The patient is a carrier of a known, BRCA1, or HNPCC (hereditary non-polyposis colorectal cancer or Lynch syndrome, hMLH1, hMSH2, PMS1, hMSH6, EpCAM) gene mutation, and there is \\> 1 pancreatic cancer in the family, one of whom is a first- or second-degree relative of the subject to be screened.\n* Persons with known genetic mutation should have proof of mutation status. Those who had research-related genetic testing must have confirmation by a clinical CLIA-certified laboratory.\n* Patients must have a pancreatic imaging abnormality that is being followed by pancreatic imaging surveillance (EUS and/or MRI and /or CT), such as a pancreatic cyst consistent with an IPMN or parenchymal abnormalities consistent with PanIN.\n* Patients must have adequate organ and marrow function defined by study-specified laboratory tests prior to initial study drug.\n* Ability to understand and willingness to sign a written informed consent document.\n* Woman of childbearing potential must have a negative pregnancy test and follow contraceptive guidelines as defined per protocol.\n* Men must use acceptable form of birth control while on study.\n\nExclusion Criteria:\n\n* If expected to require any other form of systemic or localized antineoplastic therapy while on study.\n* Within 4 weeks prior to first dose of study drug.\n\n  o Any systemic or topical corticosteroids at immunosuppressive agents.\n* Within 4 weeks prior to first dose of study drug.\n\n  * Any investigational device.\n  * Has received a live vaccine.\n  * Received any allergen hyposensitization therapy.\n  * Any major surgery.\n* Infection with HIV or hepatitis B or C.\n* Uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, metastatic cancer, or psychiatric illness/social situations that would limit compliance with study requirements monoclonal antibody.\n* Has a diagnosis of immunodeficiency.\n* Any other sound medical, psychiatric, and/or social reason as determined by the Investigator.\n* Unwilling or unable to follow the study schedule for any reason.\n* Are pregnant or breastfeeding.",
            "healthyVolunteers": true,
            "sex": "ALL",
            "minimumAge": "40 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Colleen Apostal, RN",
                    "role": "CONTACT",
                    "phone": "410-614-3644",
                    "email": "GIClinicalTrials@jhmi.edu"
                },
                {
                    "name": "Joann Santmyer, RN",
                    "role": "CONTACT",
                    "phone": "410-614-3644",
                    "email": "GIClinicalTrials@jhmi.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Neeha Zaidi, MD",
                    "affiliation": "Sidney Kimmel Comprehensive Cancer Center at the Johns Hopkins Medical Institution",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Sidney Kimmel Comprehensive Cancer Center",
                    "status": "RECRUITING",
                    "city": "Baltimore",
                    "state": "Maryland",
                    "zip": "21231",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Trish Brothers, RN",
                            "role": "CONTACT",
                            "phone": "410-614-3644",
                            "email": "GIClinicalTrials@jhmi.edu"
                        },
                        {
                            "name": "Joann Santmyer, RN",
                            "role": "CONTACT",
                            "phone": "410-614-3644",
                            "email": "GIClinicalTrials@jhmi.edu"
                        },
                        {
                            "name": "Neeha Zaidi, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.29038,
                        "lon": -76.61219
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000010190",
                    "term": "Pancreatic Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000004067",
                    "term": "Digestive System Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000004701",
                    "term": "Endocrine Gland Neoplasms"
                },
                {
                    "id": "D000004066",
                    "term": "Digestive System Diseases"
                },
                {
                    "id": "D000010182",
                    "term": "Pancreatic Diseases"
                },
                {
                    "id": "D000004700",
                    "term": "Endocrine System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M3585",
                    "name": "Adenocarcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M13110",
                    "name": "Pancreatic Neoplasms",
                    "asFound": "Pancreatic Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7256",
                    "name": "Digestive System Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M8886",
                    "name": "Gastrointestinal Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M7863",
                    "name": "Endocrine Gland Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M7255",
                    "name": "Digestive System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8883",
                    "name": "Gastrointestinal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M13102",
                    "name": "Pancreatic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M7862",
                    "name": "Endocrine System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T4387",
                    "name": "Pancreatic Cancer",
                    "asFound": "Pancreatic Cancer",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC06",
                    "name": "Digestive System Diseases"
                },
                {
                    "abbrev": "BC19",
                    "name": "Gland and Hormone Related Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000019531",
                    "term": "Poly ICLC"
                }
            ],
            "ancestors": [
                {
                    "id": "D000007369",
                    "term": "Interferon Inducers"
                },
                {
                    "id": "D000007155",
                    "term": "Immunologic Factors"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M2853",
                    "name": "Immunomodulating Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M17360",
                    "name": "Vaccines",
                    "relevance": "LOW"
                },
                {
                    "id": "M280480",
                    "name": "Poly ICLC",
                    "asFound": "Combination Chemotherapy",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10407",
                    "name": "Interferons",
                    "relevance": "LOW"
                },
                {
                    "id": "M10201",
                    "name": "Immunologic Factors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                },
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                }
            ]
        }
    },
    "hasResults": false
}